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Misoprostol is being used in obstetrics especially during the first and third trimesters of pregnancy. It has 
become a good drug for prevention and treatment of postpartum haemorrhage. It is considered a safe drug 
with few side effects. However, we present a report of a rare severe hypersensitivity reaction in a patient 
who had sublingual misoprostol for prevention of postpartum haemorrhage. 
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Case Report
INTRODUCTION
isoprostol is a synthetic analogue of 
Mprostaglandin E1.  I ts  chemical (International Union of Pure and 
Applied Chemistry) name is Methyl 7-(1R,2R,3R)-
3-hydroxy-2-(S,E)-4-hydroxy-4-methyloct-1-
1enyl)-5-oxocyclopentyl-heptanoate.  It  is 
©
marketed as cytotec  by Pzer. It was originally 
registered for preventing gastric ulcer as it binds 
to prostaglandin receptors at the parietal cells, 
stimulates G  pathway, thereby decreasing i
intracellular cyclic AMP and gastric acid 
1secretion.  
However, its property to induce contraction of 
smooth muscle of the uterus was exploited in 
women's reproductive health programs. 
Misoprostol is being used in obstetrics as a 
treatment of missed abortion, incomplete 
abortion, cervical preparation before surgical 
2
evacuation and induction of labor.  Misoprostol 
has proven to be effective in preventing and 
treating postpartum haemorrhage resulting from 
the failure of the uterus to contract fully after 
2
delivery.  It can be administered by oral solution, 
1
oral tablet, sublingual, rectal and vaginal routes.  
The oral solution has been shown to produce the 
3fastest and strongest uterotonic effect.  It is 
rapidly absorbed after oral administration and it 
is de-esteried to form misoprostol acid which is 
1
the active metabolite.  The therapeutic effect starts 
1within 30 minutes and peaks at 60 to 90 minutes.  
Its duration of action is up to 3 hours with an 
1elimination half-life of 20 to 40 minutes.  The 
reported adverse effects of misoprostol include 
fever, shivering, diarrhea, abdominal pain and 
4
cramp.  It is excreted mainly in the urine.
Oxytocin with inherent property of uterine 
contraction is the standard for postpartum 
haemorrhage prevention and treatment. 
However, its use in augmentation of labour in the 
cases of prolonged labour has resulted in 
desensitization of its receptors at the uterus, 
thereby impairing the post-delivery effect of 
uterine contractility and increasing the risk of 
5atonic postpartum haemorrhage.  
Therefore, the body of knowledge about efcacy 
of misoprostol resulted in the addition of 
misoprostol to the World Health Organization's 
(WHO) list of essential drugs for postpartum 
6
haemorrhage prevention and treatment in 2011.  
The evidence on misoprostol for treatment of 
postpartum haemorrhage shows it curbs 
excessive postpartum bleeding where oxytocin 
2 has shown suboptimal effect. However, we 
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describe a rare case of hypersensitivity reaction to 
misoprostol so that we become much more careful 
in its administration and avoid its random usage. 
CASE REPORT
+0A 30 year old woman, a trader, gravid 2, para 1 , 
1alive was booked for emergency caesarean 
section on account of prolonged labour with 
previous caesarian section scar. She was referred 
from a maternity home where labour was 
augmented with oxytocin and admitted at 
gestational age of 39 weeks, 4 days with 30 hour 
history of labour pain. Her past medical history 
was remarkable of previous caesarean section on 
account of obstructed labour done in a private 
hospital with no clear cut knowledge of drugs she 
received then. 
There was no history of allergy to misoprostol or 
any other drug. Her last meal was 8 hours prior to 
presentation. The clinical evaluation was 
remarkable for labour pain and laboratory result 
reviewed. The pack cell volume was 34% (only 
investigation result available) and she was 
assigned American Society of Anesthesiologist 
physical status I.  She was counseled for 
subarachnoid block and general anaesthesia in 
case of subarachnoid block failure and she gave 
consent. Her vital signs at the time of review were 
s t a b l e .  S h e  w a s  g i v e n  i n t r a v e n o u s 
metoclopramide 10 mg and ranitidine 50 mg. 
She had emergency lower segment caesarean 
section under spinal anaesthesia and the surgery 
lasted 64 minutes. She was delivered of a life 
female baby who weighed 3.8 kg with APGAR 
scores of 6 at the rst minute and 9 at the fth 
minute. The estimated blood loss was 800 mls and 
intra-operative haemodynamic variables were 
stable with Oxygen saturation (SPO ) range of 95-2  
97 % at room air, Blood Pressure range of 106/68 -
146/93 mmHg, Respiratory Rate range of 16-20 
cycle per minute, Pulse Rate range of 64-92 beat 
oper minute and temperature range of 37.0-37.4 C. 
She received 2.5 litres of normal saline intra-
operatively. The uterus was not adequately 
contracted despite oxytocin infusion. The patient 
was given sublingual misoprostol 600 µg and 
transferred to the recovery room.
It was observed 15 minutes later that the patient 
was in respiratory distress with respiratory rate 
(RR) of 26 cycles per minute, SPO  was 88-90% 2
(room air), Blood Pressure (BP): 85/50 mmHg, 
Pulse Rate (PR): 142 beats per minutes and 
0
temperature was 37.7 c. She was shivering and no 
signicant bleeding per vagina. She was told to 
spit out the poorly dissolved 3 tablets of 
misoprostol (200µg each) under her tongue and 
immediately commenced on supplemental 100%  
oxygen at 4L/min via facemask. There was no 
history of pain or swelling on the lower limbs. 
Chest and lower limbs examination were 
unremarkable. She was given intravenous 
hydrocortisone 200 mg, promethazine 25 mg and 
transferred to intensive care unit. Emergency 
Chest Xray, clotting proles and d-dimer assay 
were requested. Her vital signs after 15 minutes 
were BP: 90/54 mmHg, PR: 104 beats per minute, 
RR: 24 cycles per minute, SPO : 92 % and 2
otemperature: 37.6 c. 
She was continued on intravenous normal saline 1 
litre at 120 ml/min. There were improvement in 
her vital signs within 1 hour; BP: 102/63 mmHg, 
PR: 100 beats per minutes, RR: 24 cycles per 
ominutes, SPO : 96%, temperature: 37.5 c and 2
shivering stopped. Patient was observed for the 
next 8 hours and she was stable with RR dropped 
to 18 cycles per minute with SPO : 94 % (room air). 2
Chest Xray revealed no signicant ndings and 
the clotting proles within the limit of normal. The 
d - d i m e r  a s s a y  w a s  n o t  d o n e .  S h e  w a s 
subsequently transferred to the ward, seen 24 
hours later by the team and was stable with 
adequate contraction of the uterus.
DISCUSSION
Anaphylaxis is a clinical syndrome that affects 
multiple organ systems especially cardiovascular 
and respiratory symptoms with compromised 
1haemodynamic variables.  Clinically, there is 
always hypotension with attendant poor 
perfusion of vital organs as we witnessed in the 
index case. Respiratory system may witness poor 
gaseous exchange following bronchospasm and 
dyspnea with decrease in oxygen saturation. In the 
index case, there was early recognition of the 
decrease in the oxygen saturation, hence the 
 
immediate intervention.
At the molecular level, anaphylaxis involves 
degranulation of mast cells and basophils with 
release of immunoglobin E and pro-inammatory 
mediators  fol lowing re-exposure to  the 
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probable that the patient received misoprostol 
during her rst caesarian section and upon the 
second exposure, developed the anaphylaxis. 
7Madaan et al  reported similar hypersensitivity 
reaction following administration of misoprostol 
through the vaginal route for management of 
missed abortion in a primigravida. However, 
when there is no prior antigen exposure, it 
8becomes anaphylactoid reaction.  The allergy in 
7
the report by Madaan et al  might have been 
a n a p h y l a c t o i d  r e a c t i o n .  H o w e v e r ,  t h e 
management of the patient was similar to our 
management in the index case. There was a similar 
reported of lichenoid eruptions caused by 
9misoprostol according to Cruz et al  in their study. 
10,11
On the contrary, some studies  showed the 
protective property of misoprostol in allergic 
10
diseases. Babakhin et al  demonstrated that 
misoprostol can inhibit basophil histamine 
release, indicating a potentially benecial role of 
misoprostol as pharmacotherapy for allergic 
diseases. . Misoprostol might have suppressed the 
absorption of the allergen levels and outbreak of 
the allergic symptoms induced by aspirin in the 
patients with wheat dependent exercise induced 
11anaphylaxis.  Despite these, misoprostol allergy 
still occurs. Hence, clinicians should be aware of 
the possibility of allergy as a rare adverse effect as 
the use of misoprostol in women's reproductive 
health programs continues to increase.
Therefore, early detection and immediate 
treatment of this rare drug allergy is vital to save 
life as was done in the index case. Immediate 
laboratory and radiological tests are paramount to 
rule out pulmonary embolism, especially d-dimer 
assay which unfortunately we had no facility for it. 
Documentation of the misoprostol allergy in the 
patient's case le and adequate clerking are very 
necessary steps to forestall such allergy. 
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